Rocky Mountain elk (Cervus elaphus nelsoni) are resilient, adaptable members of the cervid family. Much like whitetailed deer (Odocoileus virginianus), they thrive in a variety of habitats including the wildland-urban interface. When elk become locally overabundant, this plasticity can lead to a variety of human-wildlife conflicts and collateral effects, which may be ecological, sociological, or political in scope (Thompson and Henderson 1998) . Fertility control is one method, among a suite of management tools, which may assist in mitigating these conflicts (Bradford and Hobbs 2008) .
The idea and science of wildlife fertility control is not new. For >4 decades practitioners have investigated the efficacy and practicality of manipulating wildlife reproduction using a variety of methods in a wide range of species (Fagerstone et al. 2010) ; however, for a multitude of ecological and sociopolitical reasons, wildlife contraception has not been widely adopted as a means for population management (reviewed in Powers 2011) . Recently, extended-duration immunocontraception using the self-antigen, gonadotropin releasing hormone (GnRH) has overcome some of the barriers to successful application of a fertility control agent.
Gonadotropin-releasing hormone is a small protein hormone naturally secreted in a variable pulsatile fashion from the hypothalamus (Clarke and Cummins 1982) . It controls the reproductive hormone cascade that eventually results in signaling at the gonad and ovulation in females (Hazum and Conn 1988) . A single vaccination against GnRH, using GonaCon Immunocontraceptive Vaccine (GonaCon; National Wildlife Research Center, Fort Collins, CO, USA; Miller et al. 2008) , has been found to diminish endocrine and ovarian function within the hypothalamic-pituitary-gonadal axis in captive female elk . Presumably through immunoneutralization, antibodies directed against GnRH prevent or reduce GnRH stimulation at the anterior pituitary, reduce gonadotropin release, and prevent ovulation. As antibodies wane, females tend to return to fertility (Curtis et al. 2008 , Gionfriddo et al. 2011a .
Extended infertility (!3 yr) using GonaCon has been demonstrated in captive female elk (Killian et al. 2009 ; however, efficacy is unknown under freeranging conditions. Vaccination of free-ranging white-tailed deer revealed shorter duration of efficacy and a higher apparent incidence of negative side-effects, such as injectionsite abscesses, than in captive deer (Curtis et al. 2008; Miller et al. 2008; Gionfriddo et al. 2009 Gionfriddo et al. , 2011a . The objective of this study was to determine the efficacy of GonaCon to reduce fertility in free-ranging female elk. We also sought to document and describe potential side-effects associated with vaccination.
STUDY AREA
This study was conducted in conjunction with, and used the same animals as, those described by Monello et al. (2013) . We captured elk on their winter range within Rocky Mountain National Park, Colorado, USA. Elk primarily wintered in the eastern portion of the park and adjacent Estes Valley, which included the Town of Estes Park, Colorado (40822 0 44 00 N, 105832 0 36 00 W), between 2,500 m and 2,800 m in elevation (previously described in Conner et al. [2007] and Monello et al. [2013] ).
Elk are seasonally polyestrous and breed during periods of decreasing day length. In North America, the peak of breeding season occurs between mid-September and mid-October and calving occurs from late May to early June after a gestation period of approximately 255 days (Haigh and Hudson 1993) . Elk are monotocous, nearly always giving birth to a single calf; twinning is exceptionally rare (Haigh and Hudson 1993) . Intrinsic pregnancy rates during [2003] [2004] in this elk population were previously estimated to be between 0.82 and 1.0 (Conner et al. 2007) , which was similar to rates reported for other free-ranging elk (Cook et al. 2004, Sargeant and Oehler 2007) . This population was also habituated to the presence of humans; thus, ground-darting on foot and from vehicles was a feasible and effective method of capture.
MATERIALS AND METHODS

Animals and Treatment
This study was approved by the Colorado State University Institutional Animal Care and Use Committee (no. 07-231-01) and was conducted in conjunction with adaptive management practices described in the Rocky Mountain National Park Elk and Vegetation Management Plan (National Park Service 2007) . During January 2008, we opportunistically selected and captured 120 mature adult (>2 yr) female elk using chemical immobilization and dart delivery [detailed capture methods are described in Monello et al. (2013) ]. At the time of capture, we determined pregnancy status using transrectal palpation (Greer and Hawkins 1967, Hein et al. 1991) , estimated body condition (1-5 scale; Cook et al. 2001a, b; Conner et al. 2007) , and collected 10 mL whole blood via jugular venipuncture (BD Vacutainer SST; Becton Dickinson and Co., Franklin Lakes, NJ). We randomly allocated animals into 2 groups: treated and control. We vaccinated treated females (n ¼ 60) with GonaCon (1.5 mg GnRH conjugate þ adjuvant; 1.5 mL), and control females (n ¼ 60) received physiologic saline (0.9% NaCl; 1.5 mL). While the animal was in sternal recumbancy, we placed injections mid-way between the tuber ischii of the caudal ischium and greater trochanter of the femur using a hand-held luer-lock syringe and 18-gauge, 3.8-cm needle. To facilitate injection-site relocation at necropsy, we measured (cm) and recorded the distance from the greater trochanter to the injection site.
GonaCon was prepared as previously described . The vaccine contained multiple synthetic copies of GnRH coupled to a large immunogenic carrier protein (Blue Carrier; Biosonda, Santiago, Chile) that was combined with a water-in-oil adjuvant containing killed Mycobacterium avium ssp. avium (AdjuVac, National Wildlife Research Center). We fitted all experimental elk with very high-frequency radiocollars (Advanced Telemetry Systems, Isanti, MN) marked with individually identifiable black alphanumeric codes on colored background (blue for saline-control, yellow for GonaCon-treated; Conner et al. 2007 ). Color codes were employed to avoid confusion when later culling the animals and to prevent hunters from consuming treated animals if they were harvested outside of the park. We administered long-acting penicillin (6 million IU, SQ; DuraPen; Duravet, Blue Springs, MO) to mitigate potential infection associated with capture. Once all samples were collected, we reversed the effects of immobilizing agents (as described in Monello et al. [2013] ).
Reproduction
We confirmed pregnancy status in January 2008 using serum pregnancy-specific protein-B assays from blood collected at the time of capture (Huang et al. 2000) . During the following 3 winters (Dec-Jan), we recaptured and euthanized treated and control elk (2008-2009 ¼ 10 treated, 10 control; 2009-2010 ¼ 13 treated, 12 control; 2010-2011 ¼ 20 treated, 14 control) . Additionally, one GonaCon treated elk was euthanized in April 2009 due to unrelated circumstances and her pregnancy status was included in the data set. Pregnancy in euthanized elk was determined by direct inspection of the uterus at necropsy. Capture and sampling protocols were the same as above except that we euthanized each animal using pentobarbital sodium and phenytoin sodium (45 mL IV; Euthasol; Virbac AH, Inc., Fort Worth, TX). We transported carcasses to the Colorado State University Veterinary Diagnostic Laboratory and performed complete necropsies. Prior to transport, we removed collars so the pathologist did not know treatment status at the time of necropsy. We estimated the age of each elk by removing a single central incisor at necropsy and submitting it for dental cementum annuli analysis (Matson Laboratory LLC, Milltown, MT; Hamlin et al. 2000) .
Antibody Concentrations
We measured GnRH antibody concentrations (pmol 125 IGnRH bound/mL of serum) using a previously described radioimmunoassay technique . All samples were run in a single batch. The intra-assay coefficient of variation was 7.0%. We measured GnRH binding capacity from serum samples collected prior to treatment and at the time of euthanasia, 1-3 years post-vaccination.
Adverse Side-Effects
We confirmed survival status weekly throughout the study using radiotelemetry. Additionally, we relocated each female at least bi-monthly and observed the injection site from a distance of approximately 20-100 m using binoculars. We noted obvious lameness and injection-site swelling or discharge. Similarly, prior to darting and re-capture (2009-2011), we observed each female at a distance of 10-40 m for evidence of changes in gait or lameness as well as injection-site swelling or discharge. At the time of necropsy (approx. 2-6 hr post-euthanasia), we relocated the injection site, collected a swab of the area if purulent inflammation was present, and collected 5-20 g of affected muscle tissue, which was preserved in 10% neutral buffered formalin. During the final 2 years, we measured lesion length, height, and width (cm) and calculated volume (cm 3 ). In 77 of 79 necropsies, we collected and preserved the draining internal iliac lymph node from the leg containing the injection site. We collected sections of uterine wall, cotyledon (if gravid), ovary (with corpus luteum, if present), hypothalamus, and pituitary gland, and preserved all tissues in formalin. Finally, we visually evaluated all major organs including cardiovascular, respiratory, renal, immune, and hepatic systems. If gross abnormalities were observed, we collected tissue for histopathology. We submitted swabs collected from the site of injection to the Colorado State University Veterinary Diagnostic Laboratory for aerobic, anaerobic, and mycobacterial culture. We allowed all preserved tissues to fix for 1 week and used standard histology techniques to paraffin embed, section, and stain tissues. Sections of muscle taken from the injection site were stained with Ziehl-Neelsen stain to identify acid-fast microbial organisms such as mycobacteria. A veterinary pathologist (T.R. Spraker) examined all slides for pathologic changes in tissue architecture and evidence of inflammation.
Analysis
We used information-theoretic model selection to evaluate the ability of treatment and individual characteristics to explain the pregnancy status of adult female elk. To assess the importance of these parameters on pregnancy, we developed 11 candidate models that included treatment group (GonaCon-treated or saline control), time since injection (yr of study), age, and body condition. A priori hypotheses and model formulation was based on factors known to influence pregnancy status in elk (Stewart et al. 2005 ), and we examined both the additive and interactive effects of study year and treatment and study year and body condition. Intercept-only and global models were also included in model selection procedures. We used generalized linear models with a binomial distribution and logit link for model selection (Hardin and Hilbe 2007) . Pregnancy status of each individual was the sample unit. We conducted a goodness-of-fit test to assess the ability of model parameters to explain pregnancy by comparing the global model against the intercept-only model (Franklin et al. 2000) . We proceeded with model-selection procedures only if global models provided a better fit than intercept-only models (a ¼ 0.05). We calculated Akaike's Information Criterion (corrected for small sample size; AIC c ) and ranked the models based on differences between the best approximating model and all other models (DAIC c ) in the candidate set. Models with a DAIC c value 2 of the best-fitting model were considered to have substantial empirical support as a best-fitting model. To better assess model structure and factors, we calculated the overdispersion factor of the best-fit model, model weight (i.e., the relative likelihood that a particular model is the best-fit model), and model-averaged estimates (AE95% unconditional confidence interval [CI] ) for the effect size of each parameter in the 95% confidence set of models (Smodel wt ! 0.95; Burnham and Anderson 2002) . We report pregnancy proportions, antibody concentrations, lesion size, and body condition scores as arithmetic means with 95% CI.
RESULTS
Vaccine Efficacy
At the time of initial capture and treatment application, the proportion pregnant in GonaCon-vaccinated females was 0.85 (CI ¼ 0.73-0.93) and in control females was 0.92 (CI ¼ 0.82-0.97). During our study, proportion of pregnant females in the treated group increased from 0.0 (CI ¼ 0.0-0.22) 1 year post-treatment to 0.65 (CI ¼ 0.41-0.85) 3 years post-treatment (Fig. 1) . Proportion pregnant in the control group varied from a low of 0.75 (CI ¼ 0.43-0.95) to a high of 0.90 (CI ¼ 0.56-1.00; Fig. 1 ).
Goodness-of-fit tests that compared the ability of the global and intercept-only model to explain pregnancy were significantly different (likelihood ratio x 2 ¼ 37.65, df ¼ 9, P < 0.001). Only 2 models were considered to have substantial support as the best-fit model for pregnancy (DAIC c of 0-2); both included the interaction treatment Â year, and one also included body condition (Table 1; overdispersion of best-fit model ¼ 0.92). Model-averaged estimates clearly indicated that the interactive effects of treatment and year had the largest influence on pregnancy status, with the greatest effects of vaccination occurring in the first year of the study (Table 2 and Fig. 1 ). The effects of vaccination persisted at a reduced level into the second year of the study, but were absent by the third year, when the pregnancy rate of treated elk more than doubled from the prior year's value (Table 2 and Fig. 1 ).
Three-year mean serum GnRH antibody concentrations in non-pregnant GonaCon-treated females (28 pmol/mL; CI ¼ 27-29) were higher than in pregnant treated females (7 pmol/mL; CI ¼ 6-8; Fig. 2 ). There was no evidence of GnRH antibodies in pretreatment serum samples from any animal (data not shown) or post-treatment control serum samples (Fig. 2) . In all GonaCon-treated females, regardless of pregnancy status, GnRH antibody concentrations were highest the first year after vaccination at 29 pmol/mL (CI ¼ 22-37) and declined to a mean of 13 pmol/mL (CI ¼ 7-18) by the third year post-treatment.
Body condition had little to no effect on pregnancy proportions (Table 2 ). Mean body condition 1-3 years posttreatment was 3.01 (CI ¼ 2.77-3.24) in control females and 3.19 (CI ¼ 2.97-3.41) in GonaCon-treated females.
Adverse Side-Effects
We did not observe any lameness or visible lesions at the site of injection prior to recapture and euthanasia. We could not detect any abnormalities externally with direct palpation of the injection site prior to euthanasia. In contrast, at the time of necropsy, all 43 GonaCon-treated females had grossly visible subcutaneous or intramuscular lesions at the injection site. Lesion size varied greatly from 1 cm 3 to 492 cm 3 . Mean lesion size in treated animals was 101 cm 3 (CI ¼ 2-199) 2 years post-treatment and 130 cm 3 (CI ¼ 87-173) 3 years post-treatment. Most contained purulent material that varied in consistency from liquid to caseate. Lesions varied from one large mass to complex multi-loculated granulomas that dissected along tissue planes. Granulomatous myositis tended to be encapsulated within a thick wall of fibroplasia with extensive collagen deposition and inflammatory cell infiltrates including macrophages, lymphocytes, plasma cells, and multinucleated giant cells. We cultured 33 of 43 injection-site lesions for anaerobic and aerobic bacteria, including mycobacteria. Approximately 6% (2/33) had microbial growth. Light growth of Staphylococcus sp. and non-hemolytic Streptococcus sp. were each cultured once. No mycobacteria species were cultured. We found acid-fast organisms consistent with mycobacteria twice within fixed tissues taken from injection sites. On 3 occasions, the draining internal iliac lymph nodes had similar pyogranulomatous inflammation as that seen at the injection site, though not to the same severity. Histology of muscle tissue collected from the area of the injection sites of control females was within normal limits and we did not find evidence of inflammatory processes. We did not identify any consistent lesions in tissues from the hypothalamic-pituitary-gonadal axis of treated or control elk. Hypothalami were within normal limits and showed no evidence of inflammatory cell infiltrates. We identified a granulosa cell tumor in the ovary of one treated female and an ovarian teratoma and a cystic ovary in 2 separate control females. All ovarian pathology was considered incidental.
DISCUSSION
A single vaccination against GnRH using GonaCon during mid-gestation successfully prevented pregnancy the following year, and was moderately effective 2 years after -2011) . Sample sizes at the time of treatment were 60/group and in each year after ranged from 10 to 20 elk/group; no elk were sampled more than once post-injection. Immunocontraception was effective for 2 years post-treatment but pregnancy proportions between treated and control elk were similar 3 years post-treatment. Table 1 . Rankings of a priori models used to determine pregnancy status in female elk at Rocky Mountain National Park, Colorado subjected to treatment with a contraceptive agent (GonaCon Immunocontraceptive Vaccine, n ¼ 44) or a control injection of saline (n ¼ 36). Rankings are based on generalized linear models with a binomial distribution and logit identity. Contraceptive treatment, year since treatment was given, and the interaction between treatment and year were the most important factors in predicting pregnancy.
Model log e (L) vaccination, but there were no clear differences in the treated and control groups by the third year of the study. Similar work in captive elk using the same vaccine formulation found that GonaCon reduced pregnancy by 50-100% for up to 3 years post-treatment , suggesting that this vaccine has a reduced duration of efficacy in free-ranging elk. This is consistent with our anti-GnRH antibody concentrations, which were neither as robust nor as persistent in free-ranging elk as captive elk ). This finding is also consistent with effects of GonaCon observed in captive versus free-ranging white-tailed deer Gionfriddo et al. 2009 Gionfriddo et al. , 2011a . No definitive cause for differences in efficacy between captive and free-ranging populations has been determined; however, it has been suggested that differences in immune-response and therefore efficacy may be attributable to variance in nutritional status, micro-or macro-parasite load or exposure, previous pathogen exposure, environmental contact with mycobacteria, or other sources of physiologic stress (Tizard 1982 , Gionfriddo et al. 2011b ). All of these factors have the potential to potentiate or inhibit the response to a novel antigen such as GnRH coupled to a mollusk protein in the GonaCon vaccine. Thus, free-ranging cervids, which generally have a lower plane of nutrition and increased number of stressors compared with captive wildlife, may not produce as vigorous an immune response. This hypothesis is supported by prior work that found diminished and less persistent GnRH antibody concentrations in freeranging versus captive white-tailed deer , Gionfriddo et al. 2011a and is in accordance with our current antibody findings.
Although there were no outwardly visible signs of lameness or dysfunction associated with vaccination, every treated animal had grossly evident inflammation at the site of injection, which varied in size and shape and contained up to 500 mL of suppuration. There was no evidence to suggest that injection-site lesions decreased in size or severity between years. This is not surprising given the vaccine is composed of non-biodegradable mineral oil and contains strongly immunogenic-killed mycobacteria similar to vaccines made with Freund's complete (FCA) and modified Freund's complete (mFCA) adjuvants (Lyda et al. 2005 , Roelle and Ransom 2009 , Ransom et al. 2011 . Other studies using GnRH vaccines or porcine zona pellucida vaccines (another type of immunocontraceptive vaccine), which use similar mycobacterial emulsion type adjuvants, did not identify injection-site lesions at the prevalence we did in this investigation (Curtis et al. 2002 , Lyda et al. 2005 , Roelle and Ransom 2009 . However, many studies did not necropsy animals post-vaccination, and in most cases exact injection-site locations were not determined to ensure accurate reassessment. In all studies where post-mortem examinations were performed, prevalence of injection-site inflammation and abscesses were higher than those that were clinically apparent antemortem (Curtis et al. 2007 (Curtis et al. , 2008 Powers et al. 2007; Gionfriddo et al. 2009 Gionfriddo et al. , 2011b . Therefore, it should not be inferred that lack of clinically evident antemortem abscess Table 2 . Model-averaged estimates of parameter effect size for those included in the 95% confidence set of models used to determine pregnancy status in female elk at Rocky Mountain National Park, Colorado subjected to treatment with a fertility control agent (GonaCon Immunocontraceptive Vaccine, n ¼ 44) or a control injection of saline (n ¼ 36). Estimates are based on generalized linear models with a binomial distribution and logit identity. formation means that these immunocontraceptive vaccines do not cause significant inflammation at the site of injection. Additional post-mortem studies across multiple species are required to determine whether this is a general trend among immunocontraceptive vaccines.
Injection-site lesions were most often sterile. Although bacteria were occasionally cultured from swabs taken of purulent inflammation at the site of injection, we postulate that these were surface contaminants. Non-hemolytic Streptococcus sp. and Staphylococcus sp. are common mammalian skin commensal organisms (Hirsh and Biberstein 2004a, b) . Given clean but not sterile collection techniques at the time of necropsy, it is not surprising that we could have inadvertently introduced small amounts of contamination at this time. Additionally, cells found at injection sites were characteristic of granulomatous inflammation, which is classically associated with the presence of mycobacteria (Ackermann 2007) . It is highly unlikely that the vaccine itself was responsible for bacterial growth at the site of injection. We suggest, as previously reported by others (Curtis et al. 2008 , Gionfriddo et al. 2011b , that the combination of killed mycobacteria and a non-biodegradable mineral oil created a long-lasting depot of immune-stimulating antigen that continued to attract macrophages and lymphocytes and incite formation of persistent pyogranulomatous inflammation. Despite substantial injection-site lesions in every animal, we did not see clinical evidence of altered locomotion or detriment to the general health and fitness of treated elk. The cumulative effects of revaccination are unknown at this time; however, the potential exists for more intense immune reactions with additional doses of mycobacterial adjuvant once the animal has been primed with an initial dose (Broderson 1989) . Additional studies, particularly on the effects of revaccination, are needed to understand the potential range of effects that could occur with long-term management programs that seek to use vaccines such as GonaCon to regulate population size.
It has been suggested that wildlife fertility control offers an alternative management technique to lethal removal. Although our study demonstrates that immunocontraception using GonaCon can decrease fertility of individual animals, there is little empirical evidence in the literature to indicate that fertility control techniques can be effectively applied on a scale large enough to limit population growth rates of free-ranging cervids, especially when immigration or emigration are important drivers of population size (Merrill et al. 2006 , Ransom et al. 2014 . Jurisdictional boundaries rarely contain entire populations of highly mobile and often migratory cervids, which poses a significant challenge for treating sufficient proportions of a functionally continuous population unless all affected wildlife management agencies are in agreement that this is a preferred management strategy. There are substantial limitations to the populationlevel efficacy of fertility control even within closed populations of cervids with high reproductive and survival rates (Hobbs et al. 2000) . Additionally, there are potentially large ecological effects-such as changes to natural selection, effects on social structures and reproductive behavior, timing of mating and birthing seasons, changes to longevity, and effects on migratory or movement patterns-that still need to be examined in free-ranging populations prior to use as a management tool (Cooper 2004 , Powers 2011 , Ransom et al. 2014 .
Our data indicate that a single injection of GonaCon will significantly decrease reproduction in free-ranging female elk. However, this does not resolve the more important question, which asks whether this equates to a viable tool for managing human-wildlife conflicts in the future. Only by engaging in socio-political discourse with interested stakeholder groups informed by knowledge of population-level effects will we discover whether the costs and benefits of wildlife fertility control are adequately balanced to seriously consider contraceptive technology a practical wildlife management alternative.
